ES2176245T3 - Anticuerpos de ramapicinas de ciclo abierto. - Google Patents

Anticuerpos de ramapicinas de ciclo abierto.

Info

Publication number
ES2176245T3
ES2176245T3 ES94915854T ES94915854T ES2176245T3 ES 2176245 T3 ES2176245 T3 ES 2176245T3 ES 94915854 T ES94915854 T ES 94915854T ES 94915854 T ES94915854 T ES 94915854T ES 2176245 T3 ES2176245 T3 ES 2176245T3
Authority
ES
Spain
Prior art keywords
rapamycin
antibodies
ramapicin
same
open cycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94915854T
Other languages
English (en)
Inventor
Eduardo Gonzalez
John C Russell
Katherine L Molnar-Kimber
Craig E Caufield
Timothy D Ocain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Application granted granted Critical
Publication of ES2176245T3 publication Critical patent/ES2176245T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE PROPORCIONAN CONJUGADOS DE RAPAMICINA QUE SON UTILES COMO MOLECULAS INMUNOGENETICAS PARA LA GENERACION DE ANTICUERPOS ESPECIFICOS PARA RAPAMICINA O UN DERIVADO DE LA MISMA, PARA MEDIR NIVELES DE RAPAMICINA O DERIVADOS DE LA MISMA; PARA AISLAR PROTEINAS QUE ENLAZAN RAPAMICINA; Y DETECTAR ANTICUERPOS ESPECIFICOS PARA RAPAMICINA O DERIVADOS DE LA MISMA. ESTA INVENCION TAMBIEN PROPORCIONA ANTICUERPOS MONOCLONALES ESPECIFICOS PARA RAPAMICINA O UN DERIVADO ABIERTO DE ANILLO DE RAPAMICINA.
ES94915854T 1993-04-23 1994-04-22 Anticuerpos de ramapicinas de ciclo abierto. Expired - Lifetime ES2176245T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5303093A 1993-04-23 1993-04-23
US22420594A 1994-04-14 1994-04-14

Publications (1)

Publication Number Publication Date
ES2176245T3 true ES2176245T3 (es) 2002-12-01

Family

ID=26731364

Family Applications (2)

Application Number Title Priority Date Filing Date
ES01120777T Expired - Lifetime ES2295093T3 (es) 1993-04-23 1994-04-22 Conjugados y anticuerpos de rapamicina.
ES94915854T Expired - Lifetime ES2176245T3 (es) 1993-04-23 1994-04-22 Anticuerpos de ramapicinas de ciclo abierto.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES01120777T Expired - Lifetime ES2295093T3 (es) 1993-04-23 1994-04-22 Conjugados y anticuerpos de rapamicina.

Country Status (8)

Country Link
US (2) US6328970B1 (es)
EP (2) EP1181938B1 (es)
JP (3) JPH08509499A (es)
AU (1) AU686629B2 (es)
CA (1) CA2161101A1 (es)
DE (2) DE69435044T2 (es)
ES (2) ES2295093T3 (es)
WO (1) WO1994025022A1 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9307491D0 (en) 1993-04-08 1993-06-02 Sandoz Ltd Organic compounds
USRE40596E1 (en) * 1993-04-08 2008-12-02 Novartis Ag Rapamycin assay
DE69435044T2 (de) 1993-04-23 2008-09-18 Wyeth Rapamycin - Konjugate und Antikörper
US7279561B1 (en) * 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
US6709873B1 (en) 1997-04-09 2004-03-23 Isodiagnostika Inc. Method for production of antibodies to specific sites of rapamycin
US7078495B1 (en) 1999-08-03 2006-07-18 Dade Behring Inc. Monoclonal antibodies to tacrolimus and immunoassay methods for tacrolimus
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
EP1389209B1 (en) * 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
JP4547911B2 (ja) * 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
WO2003097647A1 (en) * 2002-05-15 2003-11-27 Endocyte, Inc. Vitamin-mitomycin conjugates
EP2181704B1 (en) 2002-12-30 2015-05-06 Angiotech International Ag Drug delivery from rapid gelling polymer composition
DK1592457T3 (da) 2003-01-27 2012-10-22 Endocyte Inc Folat-vinblastin-konjugat som lægemiddel
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
ES2425167T3 (es) * 2004-03-10 2013-10-11 Seradyn, Inc. Inmunoensayos para everolimús
AU2005238432A1 (en) * 2004-04-14 2005-11-10 Wyeth Process for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
JP5149620B2 (ja) 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド ２価リンカーおよびその結合体
MX2007001676A (es) * 2004-08-10 2007-04-12 Wyeth Corp Derivados de 42-ester de rapamicina con acido 2,2-bis(hidroximetil)propionico y metodos para hacer los mismos.
US8021849B2 (en) 2004-11-05 2011-09-20 Siemens Healthcare Diagnostics Inc. Methods and kits for the determination of sirolimus in a sample
CA2590254A1 (en) 2004-12-20 2006-06-29 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
AU2005319454B2 (en) 2004-12-20 2012-08-09 Wyeth Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
EP1863816B1 (en) * 2005-03-16 2014-06-25 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
US7189582B2 (en) * 2005-04-27 2007-03-13 Dade Behring Inc. Compositions and methods for detection of sirolimus
AU2006279304A1 (en) * 2005-08-19 2007-02-22 Endocyte, Inc. Multi-drug ligand conjugates
EP2382995A3 (en) * 2005-08-19 2013-09-25 Endocyte, Inc. Ligand conjugates of Vinca alkaloids, analogs and derivatives
CA2629714A1 (en) 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of an mtor inhibitor to treat patients with cancer
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
CN103330694A (zh) 2006-11-14 2013-10-02 阿里亚德医药股份有限公司 口服制剂
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
WO2008065887A1 (en) * 2006-11-27 2008-06-05 Terumo Kabushiki Kaisha Process for producing o-alkylated rapamycin derivative, and o-alkylated rapamycin derivative
US7914999B2 (en) 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
CA2673296C (en) 2006-12-29 2012-10-16 Abbott Laboratories Improved assay for immunosuppressant drugs
CA2673314C (en) 2006-12-29 2014-03-11 Abbott Laboratories Non-denaturing lysis reagent for use with capture-in-solution immunoassay
WO2008082979A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Diagnostic test for the detection of a molecule or drug in whole blood
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN104127878A (zh) * 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
JP2010523566A (ja) * 2007-04-05 2010-07-15 ワイス エルエルシー ワートマニン−ラパマイシンコンジュゲートおよびその使用
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
BRPI0812970A2 (pt) * 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
WO2009089549A1 (en) 2008-01-11 2009-07-16 Massachusetts Eye & Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
CN101676291B (zh) 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
ES2574606T3 (es) * 2009-11-26 2016-06-21 National Taiwan University Una sustancia activa contra el cáncer de Antrodia camphorata, método de preparación de la misma y uso de la misma
WO2013110538A1 (en) 2012-01-27 2013-08-01 Novo Nordisk A/S Injection device with a sliding scale
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
EP2908818A4 (en) 2012-10-16 2016-07-13 Endocyte Inc CONJUGATES OF DRUG DELIVERY CONTAINING ARTIFICIAL AMINO ACIDS AND METHODS OF USE
US9121859B2 (en) 2012-12-04 2015-09-01 Siemens Healthcare Diagnostics Inc. Compounds and methods for determination of FKBP-binding immunosuppressant drugs
US9593356B2 (en) 2013-06-11 2017-03-14 Takara Bio Usa, Inc. Protein enriched microvesicles and methods of making and using the same
TW201511785A (zh) 2013-07-17 2015-04-01 Sanofi Sa 顯示器總成及施配裝置
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN105461738B (zh) * 2014-06-03 2019-03-08 中国人民解放军军事医学科学院毒物药物研究所 一种雷帕霉素衍生物、其制备方法、其药物组合物及用途
AU2016278040B2 (en) * 2015-06-16 2019-07-04 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
ES2804251T3 (es) 2016-03-14 2021-02-05 Wisconsin Alumni Res Found Conjugados y micelas de ácido oligoláctico con eficacia anticáncer mejorada
CN118027062B (zh) * 2023-11-03 2025-02-14 沈阳药科大学 一种雷帕霉素前药及其纳米制剂的制备和应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4885171A (en) 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4401653A (en) 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5169773A (en) 1984-10-04 1992-12-08 Sandoz Ltd. Monoclonal antibodies to cyclosporins
EP0201751A2 (en) * 1985-05-08 1986-11-20 Abbott Laboratories 4'-aminomethyfluorescein derivatives for use in fluorescence polarization immunoassys
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
EP0238801A1 (de) 1986-02-19 1987-09-30 Siemens Aktiengesellschaft Mehrpolige elektrische Steckverbindung
EP0283801A3 (en) 1987-03-27 1990-05-30 Abbott Laboratories Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies
DE3886265T2 (de) 1987-06-05 1994-04-28 Fujisawa Pharmaceutical Co Anti-FR-900506-Stoffe-Antikörper und höchstempfindliches Enzym-Immunoassay-Verfahren.
US5089390A (en) 1987-09-04 1992-02-18 Syntex (U.S.A.) Inc. 2-methyl-4-hexene- and 2-methyl-4-heptene-1,2-diol derivatives
JPH0633315B2 (ja) * 1988-01-25 1994-05-02 ベーリンガー・マンハイム・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング ハプテン誘導体、その製法、ハプテン／蛋白質―接合体、その製法、抗体の製法及びイムノアッセイの標識酵素
CA2004626A1 (en) 1988-12-05 1990-06-05 Bernard F. Erlanger Derivatives of cyclosporine a, antibodies directed thereto and uses thereof
DK0455735T3 (da) 1989-01-30 1994-12-12 Epitope Inc Avidin-biotin assisteret immunoassay
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5122511A (en) 1990-02-27 1992-06-16 Merck & Co., Inc. Immunosuppressive cyclosporin analogs with modified amino acids at position-8
US5023264A (en) * 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
EP0473961B1 (en) 1990-08-15 1996-01-03 Abbott Laboratories Immunoassay reagents and method for determining cyclosporine
US5130307A (en) 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
PT98990A (pt) * 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5233036A (en) * 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
DE69121844T2 (de) 1990-11-20 1997-01-23 Behringwerke Ag Immunotest für Cyclosporin
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5225543A (en) 1991-03-28 1993-07-06 American Cyanamid Company Receptors method for purification of g protein-linked
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
IL101353A0 (en) 1991-04-03 1992-11-15 American Home Prod Pharmaceutical compositions for treating diabetes
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5194447A (en) 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5091389A (en) 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5102876A (en) 1991-05-07 1992-04-07 American Home Products Corporation Reduction products of rapamycin
US5138051A (en) 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US6287792B1 (en) 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
ATE135583T1 (de) 1991-06-18 1996-04-15 American Home Prod Verwendung von rapamycin zur behandlung von t- zellen lymphom/leukämie bei erwachsenen
US5169851A (en) 1991-08-07 1992-12-08 American Home Products Corporation Rapamycin analog as immunosuppressants and antifungals
US5164495A (en) * 1991-09-18 1992-11-17 Abbott Laboratories Method for preparing a dicarboxylic acid half-acid ester of FK506
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
AU3922493A (en) * 1992-04-07 1993-11-08 Dana-Farber Cancer Institute, Inc. Inhibition of P70 S6 kinase
AU4400593A (en) * 1992-06-05 1994-01-04 Abbott Laboratories Methods and reagents for the determination of immunosuppressive agents
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5252579A (en) 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
GB9307491D0 (en) 1993-04-08 1993-06-02 Sandoz Ltd Organic compounds
DE69435044T2 (de) 1993-04-23 2008-09-18 Wyeth Rapamycin - Konjugate und Antikörper
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US6187547B1 (en) 1993-09-08 2001-02-13 Novartis Ag Assay kit
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5912253A (en) 1993-12-17 1999-06-15 Novartis Ag Rapamycin derivatives
EP0833828B1 (en) 1995-06-09 2002-11-20 Novartis AG Rapamycin derivatives

Also Published As

Publication number Publication date
JP2004168782A (ja) 2004-06-17
EP1181938A2 (en) 2002-02-27
WO1994025022A1 (en) 1994-11-10
AU686629B2 (en) 1998-02-12
DE69435044D1 (de) 2007-12-27
EP0710110A1 (en) 1996-05-08
DE69430060T2 (de) 2002-11-07
DE69435044T2 (de) 2008-09-18
EP1181938A3 (en) 2002-03-20
US6328970B1 (en) 2001-12-11
US6541612B2 (en) 2003-04-01
DE69430060D1 (de) 2002-04-11
US20010010920A1 (en) 2001-08-02
EP0710110B1 (en) 2002-03-06
JPH08509499A (ja) 1996-10-08
CA2161101A1 (en) 1994-11-10
JP2004149542A (ja) 2004-05-27
EP0710110A4 (en) 1997-06-18
AU6772094A (en) 1994-11-21
ES2295093T3 (es) 2008-04-16
EP1181938B1 (en) 2007-11-14

Similar Documents

Publication Publication Date Title
ES2176245T3 (es) Anticuerpos de ramapicinas de ciclo abierto.
ES2110230T3 (es) Ensayo de rapamicina.
ATE282091T1 (de) Immunsuppressive proteinziele
ATE361364T1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
ES2157994T3 (es) Inhibidores tetra y pentapeptidos sustituidos de la proteina farnesiltransferasa.
DK1181318T3 (da) Monoklonale antistoffer samt syntetiske og bioteknologiske derivter deraf, der virker som NGF-antagonistmolekyler
DE69720732D1 (de) Substituierte Triazolo-Pyridazin-Derivate als Liganden von GABA-Rezeptoren
ES2175231T3 (es) Nuevas anfetaminas activadas.
DE69128273D1 (de) Für toxin b von clostridium difficile spezifische monoklonale antikörper
FI964845A7 (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
EA199900326A1 (ru) Промежуточные соединения и способ получения оланзапина
ES2158134T3 (es) Reactivo para la eliminacion de perturbaciones, especifico para ciertas clases de anticuerpos.
FR2780062B1 (fr) Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
BR0015872A (pt) Agentes antitrombóticos
EA200200974A1 (ru) Моноклональные антитела к рецептору лпнп человека, их получение и применение
EA199800753A1 (ru) Бензотиофены, составы их содержащие и способы с их использованием
MXPA04004018A (es) Metodos de separacion por exclusion para toxicidad de compuestos de prueba.
ES2052913T3 (es) Ensayo inmunoquimico en cuanto al factor estimulante de colonias de granulocitos-macrofagos.
DK0380443T3 (da) Monoklonale antistoffer specifikke for hirudin
EA199900840A1 (ru) Экспрессия связывающих гербицид полипептидов в растениях для получения их устойчивости к гербицидам
EA199800029A1 (ru) СПОСОБ ПОЛУЧЕНИЯ БЕНЗО[b]ТИОФЕНОВ
EA199800027A1 (ru) СПОСОБ СИНТЕЗА БЕНЗО[b]ТИОФЕНОВ
EA199800040A1 (ru) СПОСОБ СИНТЕЗА БЕНЗО/b/ТИОФЕНОВ
GT199500014A (es) Inmunoensayo para tetracloroisoftalonitrilo (clonotalonilo (mr)), sus derivados y productos de descomposicion
DK0513227T3 (da) Monoklonale antistoffer, der skelner mellem prote iner med nativ og modificeret sekvens